Research Indicates ProAlgaZyme May Decrease Risk of Stroke or Heart
Attack
Tempe
AZ, 20 January 2004
Algae
Extract Degrades Abnormal Fibrin Debris Known to Create Blood Vessel
Blockage
Health
Enhancement Products, Inc., today announced that an independent
study conducted by the Biochemistry Department at Arizona State
University concluded that the Company's flagship product, ProAlgaZyme,
possesses fibrinolytic properties, required in the breakdown of
pathological fibrin gel, thus decreasing the risk of a stroke or
heart attack.
Pathological
or abnormal fibrin gel is a result of free radicals activating the
coagulation or clotting mechanism in the body creating a soluble
substance. This soluble fibrin gel may cause a thickening of the
blood, reducing the flow and possibly creating blockages in smaller
blood vessels. These blockages are a leading cause of strokes and
heart attacks.
The
fibrin gel will also coat many of the body's defense mechanisms
such as small antibodies, white blood cells, and other immune complexes,
restricting their effectiveness. In the case of free-floating cancer
cells, the gel covers the cells and prevents the immune system from
identifying them.
As
an individual becomes older, he or she not only has greater exposure
to toxic free radicals, but the natural production of proteolytic
enzymes becomes less. The in vitro (test-tube) studies conducted
at Arizona State University found that ProAlgaZyme, a plasmin-like
enzyme, will neutralize the toxic or free radical- acting soluble
fibrins that are released into the body, thereby enhancing the degradation
of pathological soluble fibrin gel.
DeWall
J. Hildreth, DO, Director of Medical Research of Health Enhancement
Products, Inc., commented, "Clinical research studies over the past
three years have consistently shown a suppression of free radical
activity caused by tissue destruction in acute and chronic diseases.
This detoxification or neutralization of the free radical toxins
is accomplished by a proteolytic enzyme called plasmin, which the
body produces naturally, but becomes less efficient with age. The
Biochemistry Department at Arizona State University has confirmed
that the natural fresh water algae plant, exclusive to Health Enhancement
Products, Inc. and used to create ProAlgaZyme, produces an active
enzyme with the same characteristics as plasmin. As a result, ProAlgaZyme
can effectively breakdown the soluble gel and limit the risk of
a heart attack or stroke."
Howard
Baer, Chief Executive Officer of Health Enhancement Products, Inc.,
said, "The study provides conclusive evidence of the efficacy of
ProAlgaZyme. We have done extensive testing internally on AIDS/HIV,
diabetes, cancer, chronic fatigue syndrome and other chronic disabilities
using this product. However, this is the first test conducted by
an independent third party that have confirmed some of our results.
We are extremely encouraged with the findings and are confident
that once the market becomes aware of the results, it will help
generate increased demand worldwide for our ProAlgaZyme product."
"Concurrent
with the testing at Arizona State University, we have rebranded
our ReplenTish line of products and launched more consumer-friendly
packaging. We are in discussions with several major retailers and
are optimistic about our prospects for 2004."
About
Health Enhancement Products, Inc.
Health
Enhancement Products, Inc. is a nutraceutical company directed specifically
at the development and marketing of supplementary health-enhancing
products using only pure, all-natural and herbal extracts. In particular,
Health Enhancement's products use beneficial herbal extracts, vitamins,
minerals, and botanical extracts in varying combinations to address
common or specific illnesses.
The
company's primary product is ProAlgaZyme, an immune system enhancer
that is produced from algae grown in 100% purified water. The algae
produces an enzyme as a means of protecting itself from exposure
to outside disease and harmful bacteria. The enzyme is then drawn
off, filtered, tested and bottled for consumption.
Recent
clinical trials performed by Health Enhancement Products have indicated
that ProAlgaZyme may increase and activate the white blood cells
in individuals whose white cells are low or inactive, in effect
enhancing the immune system. The company is currently doing internal
clinical trials on several illnesses and diseases with ProAlgaZyme,
including various types of cancer, HIV/AIDS, diabetes and Chronic
Fatigue Syndrome. For further information for Health Enhancement
Products, Inc. or ProAlgaZyme, visit their website: www.heponline.com.
Source
Health
Enhancement Products, Inc. (www.heponline.com).
|